PharmExtracta SpA ha diffuso questo post
🔬 𝗩𝗮𝗴𝗶𝗻𝗮𝗹 𝗠𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝗺𝗲, 𝗜𝗻𝗳𝗲𝗿𝘁𝗶𝗹𝗶𝘁𝘆, 𝗮𝗻𝗱 𝗔𝘀𝘀𝗶𝘀𝘁𝗲𝗱 𝗥𝗲𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝘃𝗲 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆: 𝗪𝗵𝗮𝘁 𝗗𝗼𝗲𝘀 𝘁𝗵𝗲 𝗟𝗶𝘁𝗲𝗿𝗮𝘁𝘂𝗿𝗲 𝗦𝗮𝘆? An insightful interview with 𝗚𝗲𝗺𝗺𝗮 𝗙𝗮𝗯𝗼𝘇𝘇𝗶, biologist specialized in clinical embryology, nutrition, and fertility, produced by 𝗠𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝗺𝗮.𝗶𝘁, is now available online with 𝗘𝗡𝗚𝗟𝗜𝗦𝗛 𝗦𝗨𝗕𝗧𝗜𝗧𝗟𝗘𝗦 🎉 In this interview, Fabozzi discusses the growing body of evidence connecting the vaginal microbiota — especially dominance of 𝐿𝑎𝑐𝑡𝑜𝑏𝑎𝑐𝑖𝑙𝑙𝑢𝑠 𝑐𝑟𝑖𝑠𝑝𝑎𝑡𝑢𝑠 (CST I) — with reproductive health and success in Assisted Reproductive Technology (ART). She highlights how microbiota imbalances (such as CST III or IV) are linked to reduced chances of pregnancy, increased miscarriage risk, and lower ART success rates. 📊 Thanks to species-level identification, we now know that not all Lactobacilli are equally beneficial — and 𝐿𝑎𝑐𝑡𝑜𝑏𝑎𝑐𝑖𝑙𝑙𝑢𝑠 𝑐𝑟𝑖𝑠𝑝𝑎𝑡𝑢𝑠 stands out as the most protective for fertility. ✅ A major highlight: the best ART outcomes were achieved using 𝗖𝗿𝗶𝘀𝗽𝗮𝗰𝘁®, a precision probiotic based on the 𝐿𝑎𝑐𝑡𝑜𝑏𝑎𝑐𝑖𝑙𝑙𝑢𝑠 𝑐𝑟𝑖𝑠𝑝𝑎𝑡𝑢𝑠 M247 strain, which has demonstrated a significant increase in live birth rates. 🧬 Vaginal microbiota analysis is also emerging as a more effective and practical tool than endometrial sampling, with higher reliability and predictive value in reproductive medicine. 🎥 Watch the full interview on 𝗠𝗶𝗰𝗿𝗼𝗯𝗶𝗼𝗺𝗮.𝗶𝘁’s YouTube channel: https://lnkd.in/eckXaDzy #Crispact #FertilityInnovation #AssistedReproduction #WomensHealth #ClinicalEmbryology #𝐿𝑎𝑐𝑡𝑜𝑏𝑎𝑐𝑖𝑙𝑙𝑢𝑠𝑐𝑟𝑖𝑠𝑝𝑎𝑡𝑢𝑠 #Probiotics #PrecisionProbiotics